Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· March 16, 2026

Aible Launches SafeClaw Long-Running Agents and Presents at Eight Partner Booths and Sessions at NVIDIA GTC 2026

View original at finance.yahoo.com
Aible Launches SafeClaw Long-Running Agents and Presents at Eight Partner Booths and Sessions at NVIDIA GTC 2026 Aible launches SafeClaw that enables long-running agents with built-in enterprise AI governance and guardrails…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • We built our first Aible AI agent running on NVIDIA DGX Spark in 5 minutes. The ROI on Aible agents will be immediate. By reducing attorney response time on research questions we save a few hundred dollars per hour per attorney, the AI agent pays for itself within days

    60% confidence
  • Running on our NVIDIA DGX Spark in a secure air-gapped environment allows me to prototype confidently, eliminate surprise spending, and scale as we prove the ROI from each use case

    60% confidence
  • The end-to-end serverless AI platform is up to 200X more cost efficient

    60% confidence
  • What stood out was the model accuracy, because Aible eliminated hallucinations compared to other AI platforms we evaluated

    60% confidence
  • We have extensive experience running Aible agents in production and have seen firsthand how they can safely drive measurable operational impact at scale. Our proactive patient rescheduling agent has expanded from a single department to seven clinical service lines in just over a year, meaningfully improving patient access to timely care

    60% confidence
  • Enterprise long-running agents can unlock significant value - particularly across silo'd core systems - but require the kind of IT governance and model monitoring enabled by Aible SafeClaw and NVIDIA NeMo Guardrails

    60% confidence
  • Aible SafeClaw takes a different approach where users can test the plan generated by the long-running agent at setup time, approve which tools and models it can use and when, approve exactly which data sources it can access and how, and then approve that plan for ongoing operations

    60% confidence
  • Each tool that Aible SafeClaw leverages is completely deterministic and logged in the customer environment as Python code

    60% confidence
  • This project used the Aible software environment together with an NVIDIA DGX Spark / Dell Pro Max GB10 system to conduct exploratory analyses on locally stored health‑related data. We ran all model components on the standalone device so that data remained within institutional control. After internal validation, the analytical agent created on the local system was automatically transferred to the Nebius cloud environment without transferring underlying research data

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com